Taxonomy
| 010 - Normal blood and blood marrow cells |
| 015 - Cytochemistry |
| 020 - Infections |
| 020.010 - Viral infections |
| 020.020 - Bacterial infections |
| 020.030 - Parazitic infections |
| 020.040 - Fungal infections |
| 030 - Red blood cell disorders |
| 040 - Other abnormalities of red blood cells |
| 050 - White blood cell disorder |
| 055 - Other abnormalities of white blood cells |
| 060 - Disorders of platelets |
| 065 - Congenital disorders of haematopoesis |
| 067 - Bone marrow aplasias |
| 067.010 - Aplastic anaemia |
| 067.020 - Secondary bone marrow aplasia |
| 070 - Myeloproliferative neoplasms |
| 070.010 - Chronic myeloid leukaemia, BCR/ABL 1 positive |
| 070.020 - Chronic neutrophilic leukaemia |
| 070.030 - Chronic eosinophilic leukaemia, NOS |
| 070.040 - Polycythaemia vera |
| 070.050 - Primary myelofibrosis |
| 070.060 - Essential thrombocythaemia |
| 070.065 - Mastocytosis |
| 070.070 - Myeloproliferative neoplasm, unclassifiable |
| 075 - Myeloidní a lymfoidní neoplázie s eozinofilií a abnormalitami PDGFRA, PDGRFRA nebo FGFR1 |
| 080 - Myelodysplastic/ myeloproliferative neoplasms |
| 080.010 - Chronic myelomonocytic leukaemia |
| 080.020 - Atypical chronic myeloid leukaemia, BCR/ABL 1 negative |
| 080.030 - Juvenile myelomonocytic leukaemia |
| 080.040 - Myelodysplastic/myeloproliferative neoplasm, unclassifiable |
| 080.050 - Refraktory anaemia with ring sideroblasts associated with marked thrombocytosis |
| 090 - Myelodysplastic syndromes |
| 090.010 - Refraktory cytopenia with unilineage dysplasia |
| 090.020 - Refractory anaemia with ringem sideroblasts |
| 090.030 - Refractory cytopenia with multilineage dysplasia |
| 090.040 - Refractory anaemia with excess blasts I |
| 090.045 - Refrakterní anémie s excesem blastů II |
| 090.050 - Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality |
| 090.060 - Myelodysplastic syndrome, unclassifiable |
| 090.070 - Childhood myelodysplastic syndrome |
| 100 - Acute myeloid leukaemias and related precursor neoplasms |
| 100.010 - Acute myeloid leukaemias with recurrent genetic abnormalities |
| 100.010.010 - AML with t(8;21)(q22;q22), RUNX1-RUNX1T1 |
| 100.010.020 - AML with inv(16)(p13q22) or t(16;16)(p13;q22), (CBFbeta/MYH11) |
| 100.010.030 - Acute promyelocytic leukaemia (AML with t(15;17)(q22;q12), (PML/RAR alfa) and variants) |
| 100.010.040 - AML with t(9,11)(p22,q23), MLLT3-MLL |
| 100.010.050 - AML with t(6,9)(p23,q34), DEK-NUP214 |
| 100.010.060 - AML with inv(3)(q21q26.2), RPN1-EVI1 |
| 100.010.070 - AML (megakaryoblastic) with t(1,22)(p13,q13), RBM15-MKL1 |
| 100.020 - • Acute myeloid leukaemia with myelodysplasia-related changes |
| 100.020.010 - AML with prior myelodysplastic syndrome |
| 100.020.020 - AML without prior myelodysplastic syndrome |
| 100.030 - Therapy-related myeloid neoplasms |
| 100.040 - Acute myeloid leukaemia not otherwise categorised |
| 100.040.010 - Acute myeloid leukaemia, minimally differentiated |
| 100.040.020 - Acute myeloid leukaemia without maturation |
| 100.040.030 - Acute myeloid leukaemia with maturation |
| 100.040.040 - Acute myelomonocytic leukaemia |
| 100.040.050 - Acute monoblastic and monocytic leukaemia |
| 100.040.060 - Acute erythroid leukaemia |
| 100.040.070 - Acute megakaryoblastic leukaemia |
| 100.040.080 - Acute basophilic leukaemia |
| 100.040.090 - Acute panmyelosis with myelofibrosis |
| 100.040.100 - Myeloid sarcoma |
| 100.040.110 - Myeloid proliferations related to Down syndrome |
| 100.040.120 - Blastic plasmacytoid dendritic cell neoplasm |
| 100.050 - Acute leukaemias of ambiguous lineage |
| 110 - Precursor lymphoid neoplasms |
| 110.010 - Precursor lymphoid neoplasms |
| 110.010.010 - B lymphoblastic leukaemia/lymphoma |
| 110.010.020 - T lymphoblastic leukamia/lymphoma |
| 110.020 - Mature B-cell neoplasms |
| 110.020.010 - Chronic lymphocytic leukaemia/small lymphocytic lymphoma |
| 110.020.020 - B-cell prolymphocytic leukaemia |
| 110.020.025 - Splenic B-cell lymphoma/leukaemia, unclassifiable |
| 110.020.030 - Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia |
| 110.020.040 - Splenic marginal zone lymphoma |
| 110.020.050 - Hairy cell leukaemia |
| 110.020.051 - Heavy chain diseases |
| 110.020.052 - Plasma cell myeloma |
| 110.020.054 - Primary amyloidosis |
| 110.020.060 - Plasma cell leukaemia |
| 110.020.070 - Solitary plasmacytoma of bone |
| 110.020.080 - Extraosseous plasmacytoma |
| 110.020.090 - Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT- lymphoma) |
| 110.020.100 - Nodal marginal zone B-cell lymphoma |
| 110.020.110 - Follicular lymphoma |
| 110.020.120 - Mantle cell lymphoma |
| 110.020.130 - Diffuse large B-cell lymphoma |
| 110.020.135 - Lymphomatoid granulomatosis |
| 110.020.140 - Primary mediastinal (thymic) large B-cell lymphoma |
| 110.020.142 - Intravascular large B-cell lymphoma |
| 110.020.144 - ALK positive large B-cell lymphoma |
| 110.020.147 - Plasmablastic lymphoma |
| 110.020.150 - Primary effusion lymphoma |
| 110.020.160 - Burkitt lymphoma |
| 110.020.170 - B- cell lymphoma, unclassifiable |
| 120 - T-cell and NK-cell neoplasms |
| 120.020 - Mature T-cell and NK- cell neoplasms |
| 120.020.010 - T-cell prolymphocytic leukamia |
| 120.020.020 - T-cell large granular lymphocytic leukaemia |
| 120.020.023 - Systemic EBV positive T-cell lymphoproliferative disease of childhood |
| 120.020.026 - Hydroa vacciniforme –like lymphoma |
| 120.020.030 - Aggresive NK cell leukaemia |
| 120.020.040 - Adult T-cell leukaemia/lymphoma |
| 120.020.050 - Extranodal NK/T cell lymphoma |
| 120.020.060 - Enteropathy- type T-cell lymphoma |
| 120.020.070 - Hepatosplenic T-cell lymphoma |
| 120.020.080 - Subcutaneous panniculitis-like T-cell lymphoma |
| 120.020.090 - Mycosis fungoides |
| 120.020.100 - Sezary syndrome |
| 120.020.110 - Primary cutaneous CD30 positive T-cell lymphoproliferative disorders |
| 120.020.115 - Primary cutaneous gamma-delta T-cell lymphoma |
| 120.020.120 - Peripheral T-cell lymphoma, unspecified |
| 120.020.130 - Angioimunoblastic T-cell lymphoma |
| 120.020.140 - Anaplastic large cell lymphoma |
| 130 - Hodgkin lymphoma |
| 130.010 - Nodular lymphocyte predominant Hodgkin lymphoma |
| 130.020 - Classical Hodgkin lymphoma |
| 130.030 - Nodular sclerosis classical Hodgkin lymphoma |
| 130.040 - Lymphocyte-rich classical Hodgkin lymphoma |
| 130.050 - Mixed cellularity classical Hodgkin lymphoma |
| 130.060 - Lymphocyte-depleted classical Hodgkin lymphoma |
| 140 - Histiocytic and dendritic-cell neoplasms |
| 140.010 - Histiocytic sarcoma |
| 140.020 - Dendritic cell neoplasms |
| 140.020.010 - Langerhans cell histiocytosis |
| 140.020.020 - Langerhans cell sarcoma |
| 140.020.030 - Interdigitating dendritic cell sarcoma/tumour |
| 140.020.040 - Follicular dendritic cell sarcoma, not otherwise specified |
| 140.020.050 - Fibroblastic reticular cell tumour |
| 140.020.060 - Indeterminate dendritic cell tumour |
| 140.020.070 - Disseminated juvenilie xanthogranuloma |
| 150 - Post- transplant lymphoproliferative disorders (PLTD) |
| 160 - Solid tumors |
| 160.010 - Neuroblastoma |
| 160.020 - Breast carcinoma |
| 160.030 - Ovarian carcinoma |
| 160.040 - Prostate carcinoma |
| 160.050 - Rhabdomyosarkom |
| 160.055 - Gastric carcinoma |
| 160.060 - Ewingův sarkom |
| 160.070 - Small-cell bronchial carcinoma |
| 170 - Storage diseases |
| 170.010 - Gaucher disease |
| 170.020 - Niemann-Pick disease |
| 170.030 - Other storage diseases |